Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

The PD-1/PD-L1 pathway blockade can generate a good clinical response by reducing immunosuppression and provoking durable antitumor immunity. In addition to antibodies, aptamers can also block the interaction between PD-1 and PD-L1. For the in vivo application, however, free aptamers are usually too...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Yacong, Li, Xundou, Yao, Fengjiao, Duan, Jinhong, Yang, Xian-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911819/
https://www.ncbi.nlm.nih.gov/pubmed/35268583
http://dx.doi.org/10.3390/molecules27051482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911819/
https://www.ncbi.nlm.nih.gov/pubmed/35268583
http://dx.doi.org/10.3390/molecules27051482

Ejemplares similares